The event you are looking for cannot be found.
From here you can:
Source: http://events.kqed.org/events/index.php?com=detail&eID=19871
rich rodriguez the muppet movie the muppet movie mars rover mars rover trent richardson apple cup
The Columbia Teachers Association has filed a complaint against the Columbia County School Board after the board removed a section of the teachers contract before voting to approve the contract on Dec. 13.
The union sent the complaint to the Public Employees Relations Commission (PERC), a governor-appointed board of attorneys who hear labor and employment disputes.
?They violated the law,? Rich Grady, CTA business agent, said of the school board. After about 90 percent of teachers ratified the contract, the school board had the choice to either approve or deny the contract, he said. If board voted no, both sides could then return to the negotiating table.
Instead the board removed a section of the contract involving teacher assessment and then approved the contract.?What they did sets a bad precedent,? he said. By removing part of an agreed-on contract, the school board did not bargain in good faith and violated Florida law, Grady said.
?The board has done nothing wrong,? said Guy Norris, school board attorney. The board acted in the best interest of the district and teachers, he said.
The deleted part says that if state laws governing teacher assessments are changed, the district and the union will begin negotiating to find a new assessment system.
Gov. Rick Scott signed teacher merit pay into law in March, making a teacher?s income based on assessment. However, the Florida Education Association is now suing the state, questioning the law?s constitutionality.
Norris said the section was vague and ambiguous. ?Efforts were made to clarify it, but they were rejected by the union,? he said.
Grady, who is employed by the Florida Educators Association and works with other regional unions as well, said the union and the school board agreed to the section during negotiations.
He said the union knew the school board had a problem with that section before the Dec. 13 meeting. However, Grady said the section protected teachers and the district.
?I believe they got bad advice from their lawyers,? Grady said.
Superintendent Michael Millikin said the deleted section contained language that would have unintended consequences detrimental to the district and teachers.
The district must have a state-approved system to qualify for Race to the Top and other government funds, he said. The district has to consider possible outcomes of the merit pay lawsuit, such as different teacher assessment guidelines, Millikin said.
Millikin said he intends to begin negotitions on the removed section when the school district returns from winter break.
Board member Glenn Hunter said Millikin sent the contract to teachers before the board had come to a consensus on all elements of it.
Both Norris and Grady said the rest of the contract is valid. Right now everything moves ahead, except the removed section.
Everything else was done correctly except that one piece, Grady said.
?It looks like to me the only point to be negotiated is that one issue,? Norris said.
The union expects the state committee to make a decision by the end of January, although it could take longer, Grady said.
If the commission rules in the union?s favor, the district could be cited or fined, Grady said. The union will use past practices and previous case law to prove the district did not bargain in good faith. ?We think we have a good case,? he said.
Norris said that although he has not yet seen the complaint, it ?sounds like a waste of the district?s resources to me.?
Source: http://www.lakecityreporter.com/articles/2011/12/24/news/doc4ef1558ac9a68870918675.txt
new jersey weather halloween movies halloween movies new york snow new york snow braxton miller braxton miller
Dec 21 (Reuters) ? Walgreen Co (WAG.N) still believes it can succeed even if it stops filling prescriptions for Express Scripts Inc (ESRX.O) on January 1, and its stance suggests that the odds of the drugstore making up with the pharmacy benefits manager before the end of the year are remote.
Walgreen, the largest U.S. drugstore chain, has been battling with Express Scripts since June 21, when Walgreen said the companies could not agree on terms for a new contract.
Even before their old contract expires, Walgreen's decision to part ways with Express Scripts cost it a penny per share in pharmacy sales in the first quarter, and another penny per share in expenses, the company said on Wednesday.
Those costs, along with lower reimbursement rates and margins, led to an unexpected drop in quarterly profit.
Now, Walgreen is "moving on" after it made what Chief Executive Greg Wasson called "another serious attempt" to reach a deal last week, days before the contract expires on December 31.
Its shares fell as much as 8 percent, then recovered a bit and were down about 1 percent at $33.31 in afternoon trading.
Walgreen, armed with fresh survey data, said that many Express Scripts clients want to keep filling prescriptions at its stores.
Walgreen and Express Scripts appear unlikely to reach a deal by the end of the year. Even if they make amends in early 2012, as some expect, patients will already be taking their prescriptions elsewhere, dragging potentially billions of dollars in revenue away from Walgreen and putting it in the hands of its competitors, such as Caremark Corp (CVS.N).
"We remain concerned that patients could develop new buying habits as they are forced to move away from (Walgreens) to other retailers if no deal is reached," said Lazard Capital Markets analyst Tom Gallucci, who noted that once they take their prescriptions elsewhere, not all patients will come back to Walgreen even if they get the opportunity to do so.
Walgreen said it remains open to any fair and competitive offer from Express Scripts, which contends that it would only keep Walgreen in its network at rates and terms that it believes are right for its clients.
Walgreen, seeking to downplay the potential impact of the dispute on its business, has been trying to show the strength of its massive network of more than 7,810 pharmacies.
It said that more than 100 health plans, employers and various Express Scripts clients told it they either had changed PBMs or made sure patients would still have access to Walgreens pharmacies in 2012.
However, as health-care costs rise, employers and other contract managers are doing whatever they can to control spending.
"The market is moving in a direction that at this point is away from Walgreen's core strengths," said Scott Mushkin, an analyst at Jefferies & Co.
Meanwhile, CVS is showing that its decision to combine its thousands of drugstores with a pharmacy benefits management business in 2007 was expected to turn into a profitable success next year, as more companies choose its services.
While Walgreen has some partnerships, it cannot go out and negotiate prescription contracts like others such as CVS can, Mushkin said.
"Their strategic positioning appears to be a little bit off," he said. "One solution would be to beef up their retail market share."
Walgreen has used acquisitions to add to its store count before, most notably buying the Duane Reade chain in 2010.
cj wilson coriolanus coriolanus jon corzine rick perry v tech the three stooges
PRAGUE ? Czech financial officials say they do not recommend setting a date for the country to adopt the troubled euro currency because of potential costs associated with the debt crisis.
The finance ministry and central bank say the Czech Republic would face extra costs if it were to join the euro because it would have to contribute to the eurozone's bailout fund
In a joint statement released Thursday, the two institutions also said the country still has not met necessary financial criteria, including a low deficit, to join the euro.
The Czechs say it will be "vital" to monitor how the eurozone deals with its financial problems.
All non-euro countries in the EU, except Britain and Denmark, are officially committed to join the euro, though in practice they can defer that decision indefinitely."
the muppet movie mars rover mars rover trent richardson apple cup jewelry stores the firm
I am seeking Fantasy roleplay, prefferably Dark Fantasy. I like my Fantasy with some dark, blood encrusted edges. ;) I have also always liked playing villains. It's challenging, but always fun, I have no problems dieing, so long as my character had a good long run of tormenting our beloved heroes.
I of course enjoy a lot of Roleplays in a fantasy setting, from J.R.R. Tolkeins kind of writtings, to R.A. Salvatore. Even some historical fiction when the mood strikes me! I digress, I am rambling. I hope to become an active member of this site, make some friends, and share a lot of fun!
Source: http://feedproxy.google.com/~r/RolePlayGateway/~3/0XTv4IutRWE/viewtopic.php
julia child the descendants the descendants joe paterno lung cancer joe paterno lung cancer john tucker must die uk basketball
If you've had two or more sex partners in the last year, you could be a risky organ donor, at least according to a proposed federal health guideline that has drawn sharp protests from transplant experts who say it's far too broad.
Source: http://www.msnbc.msn.com/id/3036697/vp/45559793#45559793
hemlock hemlock mark rothko mark rothko wiccan pumpkin carvings mcrib
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 2-Dec-2011
Share ] Contact: Frank Leonard
frank@novocure.com
215-854-4095
Edelman Public Relations
PORTSMOUTH, NH December 2 Novocure, a commercial stage private oncology company, has announced that prominent neuro-oncologists at four clinical centers in the U.S. will be the first to provide access to its Tumor Treating Fields (TTFields) device, NovoTTF-100A System, for the treatment of recurrent glioblastoma multiforme (GBM). GBM is a deadly brain tumor affecting approximately 10,000 Americans each year.
The NovoTTF device, approved by the Food and Drug Administration in April 2011, will be available for prescription use in the U.S. initially through several noted brain cancer research centers whose staff have completed training in the use of this unique device. The neuro-oncologists and their centers are:
Novocure expects to train the following clinicians and their staff at the following clinical sites by year end:
"We are pleased to be working closely with these prestigious clinicians and their clinical staff to provide GBM patients with an effective treatment option, and one which does not have the usual debilitating side effects of traditional chemotherapy," said Gabriel Leung, Novocure's Chairman of Global Commercialization. "The clinical staff at these centers have mastered the training and received the certification needed to provide the Novocure TTF therapy to patients. We recognize and appreciate the time and effort dedicated by these individuals to ensure their patients have access to this new treatment."
GBM is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year. The median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the most aggressive and deadly forms of cancer.
TTF therapy, a novel platform technology for the treatment of solid tumors, provides physicians with a fourth treatment modality for cancer in addition to surgery, radiation therapy and chemotherapy.
TTF therapy has been shown in vitro and in vivo to effectively inhibit tumor growth by inducing cell death. TTF takes advantage of the electrical characteristics, geometrical shape and replication rate of dividing cancer cells all of which makes them susceptible to the effects of alternating electric fields. TTF therapy is delivered using non-invasive, insulated transducer arrays that are placed directly on the skin in the region of the tumor. TTF therapy does not deliver any electric current to the tissue; it does not stimulate nerves or muscles or heat the tissue. It creates an artificial, alternating electric field within the tumor which disrupts cancer cell division and can cause complete destruction of the dividing cancer cells.
About the NovoTTF-100A System
NovoTTF-100A System is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life without many of the side effects of chemotherapy. The most commonly reported side effect from NovoTTF treatment was a mild-to-moderate rash beneath the electrodes. The NovoTTF-100A has received marketing approval in the U.S. and is a CE Marked device that is cleared for sale in Europe.
The US Food and Drug Administration (FDA) has approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device.
###
About Novocure
Novocure Limited is a private oncology company pioneering a novel therapy for solid tumors. Novocure's worldwide headquarters is located in the Jersey Isle. Novocure's U.S. operations are based in Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com
Media contact:
Frank Leonard
frank@novocure.com
(215) 854-4095
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 2-Dec-2011 Share ] Contact: Frank Leonard
frank@novocure.com
215-854-4095
Edelman Public Relations
PORTSMOUTH, NH December 2 Novocure, a commercial stage private oncology company, has announced that prominent neuro-oncologists at four clinical centers in the U.S. will be the first to provide access to its Tumor Treating Fields (TTFields) device, NovoTTF-100A System, for the treatment of recurrent glioblastoma multiforme (GBM). GBM is a deadly brain tumor affecting approximately 10,000 Americans each year.
The NovoTTF device, approved by the Food and Drug Administration in April 2011, will be available for prescription use in the U.S. initially through several noted brain cancer research centers whose staff have completed training in the use of this unique device. The neuro-oncologists and their centers are:
Novocure expects to train the following clinicians and their staff at the following clinical sites by year end:
"We are pleased to be working closely with these prestigious clinicians and their clinical staff to provide GBM patients with an effective treatment option, and one which does not have the usual debilitating side effects of traditional chemotherapy," said Gabriel Leung, Novocure's Chairman of Global Commercialization. "The clinical staff at these centers have mastered the training and received the certification needed to provide the Novocure TTF therapy to patients. We recognize and appreciate the time and effort dedicated by these individuals to ensure their patients have access to this new treatment."
GBM is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year. The median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the most aggressive and deadly forms of cancer.
TTF therapy, a novel platform technology for the treatment of solid tumors, provides physicians with a fourth treatment modality for cancer in addition to surgery, radiation therapy and chemotherapy.
TTF therapy has been shown in vitro and in vivo to effectively inhibit tumor growth by inducing cell death. TTF takes advantage of the electrical characteristics, geometrical shape and replication rate of dividing cancer cells all of which makes them susceptible to the effects of alternating electric fields. TTF therapy is delivered using non-invasive, insulated transducer arrays that are placed directly on the skin in the region of the tumor. TTF therapy does not deliver any electric current to the tissue; it does not stimulate nerves or muscles or heat the tissue. It creates an artificial, alternating electric field within the tumor which disrupts cancer cell division and can cause complete destruction of the dividing cancer cells.
About the NovoTTF-100A System
NovoTTF-100A System is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life without many of the side effects of chemotherapy. The most commonly reported side effect from NovoTTF treatment was a mild-to-moderate rash beneath the electrodes. The NovoTTF-100A has received marketing approval in the U.S. and is a CE Marked device that is cleared for sale in Europe.
The US Food and Drug Administration (FDA) has approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device.
###
About Novocure
Novocure Limited is a private oncology company pioneering a novel therapy for solid tumors. Novocure's worldwide headquarters is located in the Jersey Isle. Novocure's U.S. operations are based in Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com
Media contact:
Frank Leonard
frank@novocure.com
(215) 854-4095
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2011-12/epr-nei120211.php
brandon mcinerney brandon mcinerney black friday 2011 deals nfl power rankings week 12 nfl power rankings week 12 brine turkey brine turkey
NEW YORK (TheWrap.com) ? Why is Newt Gingrich taking a jab at Fox News?
At a town hall event in South Carolina on Tuesday, the new GOP frontrunner mocked the network's analysts, suggesting that they don't know anything.
When asked a question about the HIV/AIDS vaccine, Gingrich said that he couldn't answer the question because he didn't know.
And then he added this:
"One of the real changes comes when you start running for President -- as opposed to being an analyst on Fox -- is I have to actually know what I'm talking about."
How would Gingrich know this? Because he was an analyst for Fox News. The former Speaker of the House contributed to the network until March, when Fox suspended him because of his upcoming presidential run. It then canceled the contract in May.
The same happened to Rick Santorum, but not Sarah Palin. Perhaps Fox chief Roger Ailes knew Palin wasn't going to run, seeing as many view him as the GOP kingmaker.
Gingrich's joke isn't all that surprising in and of itself. His campaign has been built on snark and savaging his critics, particularly the media.
But Fox is different. Not only did Gingrich once get paid by Fox, but he has also appeared on the network 52 times since he announced his candidacy. Per a New York Times story on Thursday, he has appeared more on Fox than any candidate save Herman Cain.
Though Fox declined to comment on Gingrich's specific words, a spokesperson did note that Gingrich appeared for a full hour on Sean Hannity's show Wednesday.
Source: http://us.rd.yahoo.com/dailynews/rss/tv/*http%3A//news.yahoo.com/s/nm/20111202/tv_nm/us_newtgingrich
dylan ratigan occupy occupy midnight madness midnight madness john henry john henry
TRAVERSE CITY, Mich. ? The Environmental Protection Agency proposed stricter requirements Wednesday for cleaning ballast water that keeps ships upright in rolling seas but enables invasive species to reach U.S. waters, where they have ravaged ecosystems and caused billions of dollars in economic losses.
The new standards would require commercial vessels to install technology strong enough to kill at least some of the fish, mussels and even microorganisms such as viruses that lurk in ballast water before it's dumped into harbors after ships arrive in port. Environmentalists whose lawsuits forced the EPA to implement rules in the first place said the new proposal is largely inadequate.
More than 180 exotic species have invaded the Great Lakes, about two-thirds of which are believed to have been carried in ballast water. Among them are zebra and quagga mussels, which have spread across most of the lakes and turned up as far away as California. Ballast water also has brought invaders to ocean coasts, including Asian clams in San Francisco Bay and Japanese shore crabs on the Atlantic seaboard.
Ballast water regulation has been debated in Congress for years but no legislation has passed because of disagreements over how strict the cleanliness standards should be.
The EPA refused for years to set rules for ballast water under the Clean Water Act, but the agency was ordered to do so by federal courts after environmental groups sued. The agency issued an industry-wide permit in 2008 requiring shippers to exchange their millions of gallons of ballast water at sea or, if the tanks were empty, rinse them with salt water before entering U.S. territory. Environmentalists sued again, saying the requirement was too weak.
The EPA's new draft permit lays out live-organism limits similar to those recommended by the International Maritime Organization in 2004, which shipping industry groups have said are achievable. The agency said its standard "is expected to substantially reduce the risk of introduction and establishment" of invasive species.
But environmental groups and some states contend those standards aren't strong enough. By making those standards the basis of the proposed federal policy, "EPA is shrinking from its duty to make sure U.S. waters are fully protected," said Thom Cmar, attorney for the Natural Resources Defense Council. "This draft permit is a half-step forward. EPA had an opportunity to solve this problem once and for all but this proposal doesn't do that."
Steve Fisher, executive director of the American Great Lakes Ports Association, said the federal plan was reasonable and noted it would expire after four years, allowing further refinement.
"We believe this represents a doable solution," Fisher said. "We also believe that once we start installing the first generation of this equipment, it will lead to second and third generations. EPA will have the opportunity to ratchet up the requirements as technology becomes available."
All sides agree a single federal standard would be preferable to an existing patchwork of federal and state policies, which the industry says is confusing and unworkable. The EPA doesn't have the authority to pre-empt state rules, but Fisher said the industry hopes many states will go with the EPA policy or a similar one under development by the Coast Guard.
In New York, rules scheduled to take effect in 2013 would require limits 100 times stronger than the international ones, while California is phasing in standards 1,000 times tougher. Shippers and officials in those states disagree over whether existing technology could meet those demands.
The industry contends that if New York proceeds with its rule, it would slam the door on the Great Lakes' international shipping because vessels from overseas must go through New York waters to reach the lakes.
The EPA's rule would apply to commercial ships that are more than 79 feet long, exempting recreational and military craft.
The agency will take public comment for 75 days and issue a final permit in November 2012. It would take effect in December 2013, although the requirement to install ballast treatment technology would be phased in for different vessel size groups. The equipment wouldn't have to be installed on individual ships until they are drydocked for regular maintenance, which Cmar said was a loophole that would give some vessels a grace period of many years.
The ballast treatment standards wouldn't apply to the biggest Great Lakes cargo ships, which reach up to 1,000 feet long, because they always remain within the lakes and would not transport ballast from overseas. Cmar said he opposed the exemption because those vessels haul ballast water between Great Lakes ports, helping scatter invasive species brought in by saltwater ships.
The Coast Guard also is developing ballast regulations, which are under review by the Office of Management and Budget and are expected to be released next year. A draft version also called for adopting the international standards but eventually setting tougher requirements.
The Republican-led U.S. House voted this month to impose the international standards and make it harder for either EPA or the Coast Guard to go further.
drew drew al franken al franken philadelphia eagles donovan mcnabb donovan mcnabb
Seems like Big G updates its browser of choice with fresh features every time we turn around, and one of Google's own, dev advocate Paul Kinlan, revealed that another spate of upgrades are arriving for Chrome early next year. The headliner is plug-and-play support for gamepads, but native support for cameras, microphones and open-source video chat framework WebRTC are on the docket too -- features that give Chrome some considerable gaming chops when combined with its existing WebGL and HTML 5 prowess and, he says, could bring OnLive to the web without plugins. If you thought Angry Birds on a browser was a great, we can't wait to see what's in store when a proper controller and integrated video chat are involved.Chrome to gain plug and play gamepad support and WebRTC video chat in 2012 originally appeared on Engadget on Fri, 25 Nov 2011 14:39:00 EDT. Please see our terms for use of feeds.
Permalink
TechCrunch | 
Edge, Paul Kinlan (Google+) | Email this | Comments
Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/rzXCTL3jrOY/
49ers best buy black friday bath and body works coupons frys ad a very gaga thanksgiving black friday walmart 2011 colt mccoy
Sorry, Readability was unable to parse this page for content.
Source: http://www.msnbc.msn.com/id/3036697/vp/45405127#45405127
tom brady aaron hernandez aaron hernandez portland news portland news tibetan mastiff manny pacquiao
